amoxycillin/clavulanate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   42 Trials   42 Trials   2742 News 


«12...56789101112131415...4546»
  • ||||||||||  Review, Journal:  Antimicrobial treatment of skin and soft tissue infections. (Pubmed Central) -  Dec 5, 2023   
    The bacterial species most frequently implicated in children are Staphylococcus aureus and Streptococcus pyogenes. Given the low incidence of methicillin-resistant S. aureus in France (<10%), the first-line antibiotic treatment is amoxicillin-clavulanate, to which an anti-toxin treatment such as clindamycin may be added for patients with overt toxin signs.
  • ||||||||||  amoxycillin/clavulanate / Generic mfg.
    Journal:  Trends in penicillin dispensing during an acute rheumatic fever prevention programme. (Pubmed Central) -  Dec 4, 2023   
    Given the low incidence of methicillin-resistant S. aureus in France (<10%), the first-line antibiotic treatment is amoxicillin-clavulanate, to which an anti-toxin treatment such as clindamycin may be added for patients with overt toxin signs. During the RFPP an increase in amoxicillin dispensing was seen in regions participating in the programme and regions outside of the programme, indicating the programmatic approach led to improved adherence to recommended first-line antibiotics.
  • ||||||||||  fosfomycin tromethamine / Generic mfg.
    Journal:  Occurrence of plasmid-mediated fosfomycin resistance (fos genes) among Escherichia coli isolates, Portugal. (Pubmed Central) -  Dec 4, 2023   
    The prevalence of fosfomycin-resistant E. coli isolates is still low in Portugal. Notably, 15% of fosfomycin-resistant isolates harbour a transferable fosA gene, among which there is a high rate of ESBL producers, turning traditional empirical therapeutical options used in Portugal (fosfomycin and amoxicillin-clavulanic acid) ineffective.
  • ||||||||||  Trial completion date, Trial primary completion date:  Early Antibiotics After Aspiration in ICU Patients (clinicaltrials.gov) -  Nov 30, 2023   
    P4,  N=100, Recruiting, 
    Therefore, routine UTI screening, regular health education on the risk of asymptomatic infectious diseases for reproductive age group females, and antimicrobial susceptibility testing should be practiced to avoid the progression of an asymptomatic infection into a symptomatic UTI. Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024
  • ||||||||||  cisplatin / Generic mfg., amoxycillin/clavulanate / Generic mfg.
    Journal:  What if amoxicillin/clavulanic acid reduces the cisplatin anticancer impact on oral cancer treatment? (Pubmed Central) -  Nov 28, 2023   
    Due to amx/cla-cisp combination on both cells but significantly on SCC-15 recovered the sole cisplatin effect, we believe that there might be a second thought when prescribing antibiotics while treating cancer patients. Not only the antibiotic's type but also the cancer type might interact to lessen the chemotherapeutic agent's impact which is clinically a dilemma to focus on.
  • ||||||||||  Journal:  BACTERIAL PROFILE, ANTIMICROBIAL RESISTANCE, AND FACTORS ASSOCIATED WITH URINARY TRACT INFECTION AMONG PREGNANT WOMEN AT HOSANNA TOWN HEALTH FACILITIES, CENTRAL ETHIOPIA. (Pubmed Central) -  Nov 27, 2023   
    The gram-positive bacteria were susceptible to gentamicin (86.4%), erythromycin (81.8%), and nitrofurantoin (77.3%): whereas they showed a high level of resistance to penicillin (72.7%), doxycycline (54.5%), trimethoprim-sulfamethoxazole (52.9%), and cefoxitin (52.9%)...Therefore, regularly, culture-based bacterial identification and antibiotic susceptibility testing should be performed. Alternatively, empiric antibiotic therapy should consider the prevalence of antibiotic-resistant uropathogens and the factor that may increase the urinary tract infection occurrence due to multi-drug resistant uropathogens.
  • ||||||||||  Journal:  Genome Analysis of Klebsiella pneumoniae Reveals International High-Risk Pandemic MDR Clones Emerging in Tertiary Healthcare Settings in Uganda. (Pubmed Central) -  Nov 25, 2023   
    There was high resistance to piperacillin (90.91%), cefuroxime (86.96%), ceftazidime (84.62%), cefotaxime (84.00%), amoxicillin/clavulanate (75%), nalidixic acid (73.68%), and nitrofurantoin (71.43%) antibiotics among K. pneumoniae isolates...Chromosomal fosA (for fosfomycin) and oqxAB efflux pump genes were detected in all isolates...Our study demonstrated genetically diverse populations of K. pneumoniae, low levels of carbapenem resistance among the isolates, and no convergence of MDR and hypervirulence. Emerging high-risk international pandemic clones (ST11, ST14, ST147, ST 86 and ST307) were detected in these healthcare settings which are difficult to treat.
  • ||||||||||  amoxycillin/clavulanate / Generic mfg.
    Review, Journal:  Dog and Cat Bites: Rapid Evidence Review. (Pubmed Central) -  Nov 24, 2023   
    Antibiotic prophylaxis, with amoxicillin/clavulanate as the first-line choice, should be considered for all bites, particularly for those at increased risk of infection...Primary closure of bite wounds may be performed if there is low risk of infection. The need for tetanus vaccination and rabies postexposure prophylaxis should be evaluated for each patient; bites that do not break the skin generally do not require rabies postexposure prophylaxis.
  • ||||||||||  rafamin (MMH-407) / Materia Medica
    Preclinical, Journal:  Efficacy of Raphamin against Pneumococcal Infection: a Preclinical Study. (Pubmed Central) -  Nov 3, 2023   
    Raphamin monotherapy significantly decreased bacterial load in the lungs in comparison with placebo (p<0.05) which was comparable to the effect in antibiotic alone or combined with Raphamin. Raphamin prevented reproduction of Streptococcus pneumoniae in the lower respiratory tract and its combination with the antibiotic was safe and did not reduce the efficacy of amoxicillin/clavulanic acid.
  • ||||||||||  Journal:  Pasteurella multocida Pneumonia with Hemoptysis in an Immunocompetent Case (Pubmed Central) -  Oct 31, 2023   
    Although Pasteurella multocida pneumonia is not commonly observed, the presence of underlying bronchiectasis in this patient facilitated the establishment of the bacteria. In order not to miss the diagnosis of pneumonia due to P.multocida, microbiological evaluation and molecular typing should be performed in the samples taken from the respiratory tract in patients with chronic respiratory diseases such as bronchiectasis.
  • ||||||||||  Journal:  Investigation of Virulence Factors, Phylogenetic Group Features, and the Presence of ST131 Clone in Escherichia coli Isolates, a Urinary Tract Infection Agent in Children (Pubmed Central) -  Oct 31, 2023   
    In recurrent UTI agents, resistance rates were higher for cefotaxime (n= 29, 29%), trimethoprim-sulfamethoxazole (n= 35, 35%) and cefepime (n= 25, 25%) and in O25b/ST131 isolates (n= 67) the rates were higher for amikacin (n= 3, 4.5%), gentamicin (n= 10, 14.9%) and ciprofloxacin (n= 17, 25.4%) when compared to the first UTI agents and non-O25b/ ST131 isolates (p< 0.05)...Thirty-three isolates belonging to 15 patients were evaluated with PFGE, and it was observed that the latter isolate and the first isolate of eight patients (53%) had the same band profile. Focusing on surveillance, diagnostic testing, treatment algorithms, and preventive measures for E.coli and especially for ST131 clone, which is frequently observed as causative agent in childhood UTIs, will help to manage challenging E.coli infections.
  • ||||||||||  Journal:  Trends in antimicrobial resistance of Shigella species in Peru, 2011-2020. (Pubmed Central) -  Oct 30, 2023   
    sonnei was the most frequent species, which have a large proportion of strains resistant to trimethoprim/sulfamethoxazole, and a growing trend of resistance to ciprofloxacin and nalidixic acid. This increase in resistance to commonly used antibiotics in treatments is alarming, threatening the control and management of these currently treatable infections.
  • ||||||||||  Journal:  Antimicrobial Susceptibility of Commensal E. coli Isolated from Wild Birds in Umbria (Central Italy). (Pubmed Central) -  Oct 27, 2023   
    The highest prevalence of resistance was observed for ampicillin (85%) and amoxicillin/clavulanic acid (47%), probably due to their extensive use in human and veterinary medicine...Resistance to ciprofloxacin, cefotaxime and ceftazidime exhibited values of 18%, 17% and 15%, respectively...was not isolated. Resistance to third-generation cephalosporins, also detected in long-distance migratory birds, suggests the need for monitoring studies to define the role of wild birds in antimicrobial resistance circuits.
  • ||||||||||  sulopenem (CP-70429) / Iterum
    Enrollment closed, Trial completion date, Trial primary completion date:  REASSURE: Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women (clinicaltrials.gov) -  Oct 27, 2023   
    P3,  N=2229, Active, not recruiting, 
    As a management decision, the maximum penetrance admitted for using a specific antibiotic for E. coli infections in pigs is recommended to be less than 20%. Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2023 | Trial primary completion date: Mar 2024 --> Nov 2023
  • ||||||||||  Journal:  Helicobacter cinaedi Infection Presenting with Myalgia and Cellulitis. (Pubmed Central) -  Oct 24, 2023   
    We suspected pyomyositis and cellulitis and started oral administration of amoxicillin-clavulanate...On day 24, antibiotic therapy was changed to intravenous ampicillin, and symptoms improved...Myalgia can be caused by pyogenic myositis because of bacteremia. In cases of myalgia or cellulitis of unknown etiology, blood cultures can be useful when bacteremia is suspected; blood samples should be monitored over an extended period.
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Trial completion date, Trial primary completion date:  APAC: Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children (clinicaltrials.gov) -  Oct 23, 2023   
    P4,  N=302, Active, not recruiting, 
    In cases of myalgia or cellulitis of unknown etiology, blood cultures can be useful when bacteremia is suspected; blood samples should be monitored over an extended period. Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
  • ||||||||||  cefazolin / Generic mfg., tetracycline / Generic mfg., amoxycillin/clavulanate / Generic mfg.
    Journal:  Detection of Antimicrobial Resistance and Biofilm Production Among Staphylococcus pseudintermedius from Canine Skin Lesions. (Pubmed Central) -  Oct 19, 2023   
    Resistance to penicillin, amoxicillin-clavulanic acid, and cefazolin were higher than other antimicrobials...Among tetracycline-resistant strains, the frequency of tetK and tetM determinants were 19 (90.47%) and 21 (100%), respectively...Furthermore, the presence of icaA/D genes was detected in 35 (100%) and 29 (82.85%) of S. pseudintermedius strains, respectively. The high rates of antimicrobial resistance and biofilm production ability among S. pseudintermedius isolates, emphasize the urgent need to use more effective infection control policies and guidelines for antimicrobial use.
  • ||||||||||  levofloxacin / Generic mfg., clindamycin phosphate / Generic mfg., amoxycillin/clavulanate / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date, Head-to-Head:  Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis (clinicaltrials.gov) -  Oct 19, 2023   
    P=N/A,  N=100, Not yet recruiting, 
    The high rates of antimicrobial resistance and biofilm production ability among S. pseudintermedius isolates, emphasize the urgent need to use more effective infection control policies and guidelines for antimicrobial use. Trial completion date: Dec 2024 --> Dec 2025 | Initiation date: May 2023 --> Nov 2023 | Trial primary completion date: Jul 2024 --> Nov 2025
  • ||||||||||  amoxycillin/clavulanate / Generic mfg.
    Journal:  Cryptic susceptibility to penicillin/?-lactamase inhibitor combinations in emerging multidrug-resistant, hospital-adapted Staphylococcus epidermidis lineages. (Pubmed Central) -  Oct 15, 2023   
    On the other hand, we also show that methicillin-resistant S. epidermidis is capable of developing increased resistance to amoxicillin/clavulanic acid during long-term in vitro exposure to these drugs. These findings suggest that penicillin/?-lactamase inhibitor combinations could be a promising therapeutic candidate for treatment of a high proportion of methicillin-resistant S. epidermidis infections, although the in vivo risk of resistance development needs to be further addressed before they can be incorporated into clinical trials.